Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.38 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8957242 | 1.00 | SLC6A5 (0.48) | SLC6A5ITGB3ITGA2BFAAHNOD1 | |
| SCHEMBL9664622 | 0.96 | SLC6A5 (0.53) | SLC6A5ITGB3ITGA2BFAAHNOD1 | |
| SCHEMBL9664611 | 0.96 | SLC6A5 (0.53) | SLC6A5ITGB3ITGA2BFAAHNOD1 | |
| SCHEMBL9664371 | 0.95 | SLC6A5 (0.54) | SLC6A5ITGB3ITGA2BFAAHNOD1 | |
| SCHEMBL20956613 | 0.95 | SLC6A5 (0.54) | SLC6A5ITGB3ITGA2BFAAHNOD1 | |
| SCHEMBL9664377 | 0.95 | SLC6A5 (0.54) | SLC6A5ITGB3ITGA2BFAAHNOD1 | |
| SCHEMBL17203886 | 0.95 | SLC6A5 (0.54) | SLC6A5ITGB3ITGA2BFAAHNOD1 | |
| SCHEMBL13279668 | 0.95 | SLC6A5 (0.54) | SLC6A5ITGB3ITGA2BFAAHNOD1 | |
| SCHEMBL19138238 | 0.95 | SLC6A5 (0.54) | SLC6A5ITGB3ITGA2BFAAHNOD1 | |
| SCHEMBL19138207 | 0.95 | SLC6A5 (0.54) | SLC6A5ITGB3ITGA2BFAAHNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112194632-A | Novel 5-acylsulfanyl-histidine compounds as precursors for the corresponding 5-sulfanylhistidines and disulfides thereof | 特瑞海德公司 | 2021-01-08 | — | — | CN | claimed |
| CN-106573895-B | Novel 5-acylsulfanyl-histidine compounds as precursors for the corresponding 5-sulfanylhistidines and disulfides thereof | 特瑞海德公司 | 2020-11-24 | — | — | CN | claimed |
| EP-3148973-A1 | NOVEL COMPOUNDS OF THE 5-ACYLSULFANYL-HISTIDINE TYPE AS PRECURSORS OF THE CORRESPONDING 5-SULFANYLHISTIDINES AND THE DISULFIDES THEREOF | Tetrahedron (FR) | 2017-04-05 | — | — | EP | claimed |
| WO-2015181507-A1 | NOVEL COMPOUNDS OF THE 5-ACYLSULFANYL-HISTIDINE TYPE AS PRECURSORS OF THE CORRESPONDING 5-SULFANYLHISTIDINES AND THE DISULFIDES THEREOF | TETRAHEDRON (FR) | 2015-12-03 | — | — | WO | claimed |
| US-20250339370-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AVANTOR PERFORMANCE MATERIALS, LLC (US) | 2025-11-06 | — | — | US | disclosed |
| CN-118255830-A | S1PR2 modulators and uses thereof | 北京昌平实验室 | 2024-06-28 | — | — | CN | disclosed |
| CN-112194632-A | Novel 5-acylsulfanyl-histidine compounds as precursors for the corresponding 5-sulfanylhistidines and disulfides thereof | 特瑞海德公司 | 2021-01-08 | — | — | CN | disclosed |
| CN-106573895-B | Novel 5-acylsulfanyl-histidine compounds as precursors for the corresponding 5-sulfanylhistidines and disulfides thereof | 特瑞海德公司 | 2020-11-24 | — | — | CN | disclosed |
| EP-3148973-A1 | NOVEL COMPOUNDS OF THE 5-ACYLSULFANYL-HISTIDINE TYPE AS PRECURSORS OF THE CORRESPONDING 5-SULFANYLHISTIDINES AND THE DISULFIDES THEREOF | Tetrahedron (FR) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015181507-A1 | NOVEL COMPOUNDS OF THE 5-ACYLSULFANYL-HISTIDINE TYPE AS PRECURSORS OF THE CORRESPONDING 5-SULFANYLHISTIDINES AND THE DISULFIDES THEREOF | TETRAHEDRON (FR) | 2015-12-03 | — | — | WO | disclosed |
| EP-0536262-A4 | SUBSTITUTED HISTIDINES | SMITHKLINE BEECHAM CORP (US) | 1996-08-14 | — | — | EP | disclosed |
| EP-0536262-A1 | SUBSTITUTED HISTIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339370-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AADAT, KYNU, PNISR | SLC6A5 3122/4885ITGB3 3803/4885ITGA2B 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.